Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Determinants for Therapy Response on Renal Cell Carcinoma
NCT02208128Unknown
- Sponsor
- Heidelberg University
- Start
- May 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of sunitinib, pazopanib, bevacizumab, everolimus, axitinib and 1 more in metastatic renal cell carcinoma (mRCC), sponsored by Heidelberg University. Primary endpoint: Time to disease progression in third line therapy at 2 years. Status: unknown.
02
Drugs
sunitinibpazopanibbevacizumabeverolimusaxitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02208128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208128.